In order to investigate the effects of PRSS35 degradation of CXCL2 on neutrophil activity in tumor progression in vivo, we generated Hepa1-6 cell lines that stably expressed mPRSS35, mCXCL2, both, or an EV control and separately inoculated these lines subcutaneously into C57BL/6J mice. The gene discussed is CXCL2; the disease is neoplasm.